ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 神経・精神領域の薬剤ハンドブック
〈各論〉
文献概要
排尿障害は過活動膀胱［OAB（overactive bladder）とも言う，トイレが近い症状］と残尿・尿閉（尿が出しにくい症状）を合わせた言葉で，一般に脳疾患はOABを，末梢神経疾患は残尿・尿閉を，多系統萎縮症や脊髄疾患はOABと残尿・尿閉を同時にきたすことが多い。このうち，OABに対して選択的β3受容体刺激薬／抗コリン薬を，残尿・尿閉に対して間欠導尿，α交感神経遮断薬，コリン作動薬を組み合わせながら投与するとよい。排尿障害の治療を積極的に行い，患者の生活の質を向上させることが望まれる。
参考文献
1）榊原隆次（編著）: 神経因性膀胱ベッドサイドマニュアル. 中外医学社, 東京, 2014
2）日本排尿機能学会, パーキンソン病における下部尿路機能障害診療ガイドライン作成委員会（編）: パーキンソン病における下部尿路機能障害診療ガイドライン. 中外医学社, 東京, 2017
3）榊原隆次, 関戸哲利, 西村かおる（編著）: 認知症の排泄ケアベッドサイドマニュアル. 中外医学社, 東京, 2020
4）榊原隆次, 内田さえ（編著）: 自律神経: 初めて学ぶ方のためのマニュアル. 中外医学社, 東京, 2022
5）Sakakibara R, Sawai S, Ogata T, Iimura A: Autonomic dysfunction in older individuals: the contributions of multiple brain diseases and diabetes. Neurol Clin Neurosci 10: 198-209, 2022
6）Sakakibara R: Lower urinary tract dysfunction in patients with brain lesions. Handb Clin Neurol 130: 269-287, 2015
7）Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H; Parkinson's Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society: a guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn 35: 551-563, 2016
8）Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, et al: Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 14: 79-89, 2017
9）Sakakibara R: The cerebellum seems not a ‘little brain’ for the autonomic nervous system. Clin Neurophysiol 130: 160, 2019［doi: 10.1016/j.clinph.2018.08.021］
10）Krhut J, Skugarevská B, Míka D, Lund L, Zvara P: Clinical utility of β3-adrenoreceptor agonists for the treatment of overactive bladder: a review of the evidence and current recommendations. Res Rep Urol 14: 167-175, 2022
11）Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, et al: Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol 77: 211-220, 2020
12）Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, et al: Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstet Gynecol 125: 1423-1432, 2015
13）Taylor-Rowan M, Kraia O, Kolliopoulou C, Noel-Storr AH, Alharthi AA, et al: Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia. Cochrane Database Syst Rev 8: CD015196, 2022［doi: 10.1002/14651858.CD015196.pub2］
14）Sakakibara R, Ogata T, Uchiyama T, Kishi M, Ogawa E, et al: How to manage overactive bladder in elderly individuals with dementia?: a combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 57: 1515-1517, 2009
15）Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, et al: Efficacy of tadalafil therapy and changes in oxidative stress levels in male patients with lower urinary tract symptoms and overactive bladder. Low Urin Tract Symptoms 12: 47-53, 2020
16）Gong QQ, Xu YQ, Xu J, Ding XY, Guo C: Meta-analysis of randomized controlled trials using botulinum toxin a at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol 10: 1618, 2020［doi: 10.3389/fphar.2019.01618］
17）Huang J, Fan Y, Zhao K, Yang C, Zhao Z, et al: Comparative efficacy of neuromodulation technologies for overactive bladder in adults: a network meta-analysis of randomized controlled trials. Neuromodulation S1094-7159(22)00752-8, 2022 [online ahead of print]［doi: 10.1016/j.neurom.2022.06.004］
18）Ito T, Sakakibara R, Nakazawa K, Uchiyama T, Yamamoto T, et al: Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience 142: 1273-1280, 2006
19）Sakakibara R, Ito T, Uchiyama T, Awa Y, Yamaguchi C, et al: Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int 81: 335-339, 2008
20）Safarinejad MR, Hosseini SY: Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol 61: 456-463, 2006
21）Roberts K, Dao A, Alfahmy A, Mitchell D, Sheyn D: Does gabapentin impact response to anticholinergics for overactive bladder? Int Urogynecol J 33: 2501-2506, 2022
22）Marencak J, Cossons NH, Darekar A, Mills IW: Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Neurourol Urodyn 30: 75-82, 2011
23）Shen SH, Jia X, Peng L, Zeng X, Shen H, et al: Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis. Int Urol Nephrol 54: 737-747, 2022
24）Johnson EU, Singh G: Long-term outcomes of urinary tract reconstruction in patients with neurogenic urinary tract dysfunction. Indian J Urol 29: 328-337, 2013
25）Yamanishi T, Homma Y, Nishizawa O, Yasuda K, Yokoyama O; SMN-X Study Group: Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. Int J Urol 21: 395-400, 2014
26）Yamaguchi C, Sakakibara R, Uchiyama T, Yamamoto T, Ito T, et al: Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 26: 807-813, 2007
27）Cao N, Gu B, Gotoh D, Yoshimura N: Time-dependent changes of urethral function in diabetes mellitus: a review. Int Neurourol J 23: 91-99, 2019
28）Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, et al: α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 69: 1091-1101, 2016
29）Sakakibara R, Uchiyama T, Asahina M, Yoshiyama M, Yamanishi T, et al: Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 13: 51-53, 2003
30）Obara K, Tanaka Y: Sustainable effects of distigmine bromide on urinary bladder contractile function. Pharmacology 105: 135-144, 2020
31）Yamamoto T, Sakakibara R, Yamanaka Y, Uchiyama T, Asahina M, et al: Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin Auton Res 16: 296-298, 2006
32）Sakakibara R, Yamaguchi C, Yamamoto T, Uchiyama T, Liu Z, et al: Imidapril, an angiotensin-converting enzyme inhibitor, can reverse loss of bladder sensation. J Neurol Neurosurg Psychiatry 77: 1100-1101, 2006
33）Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, et al: The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37: 1131-1148, 2022
34）Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, et al: The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13: 106-108, 2003
35）Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P: Desmopressin for treating nocturia in men. Cochrane Database Syst Rev 10: CD012059, 2017［doi: 10.1002/14651858.CD012059.pub2］
掲載誌情報
